Study to evaluate the pharmacokinetics of Daclizumab high yield process, after multiple subcutaneous administration, in patients with relapsing-remitting multiple sclerosis

Trial Profile

Study to evaluate the pharmacokinetics of Daclizumab high yield process, after multiple subcutaneous administration, in patients with relapsing-remitting multiple sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 15 Jun 2015 New trial record
    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top